XNCR Stock Price, Chart, Stats & News
Xencor Inc (XNCR) does not currently pay a dividend.
XNCR chart
Fundamentals
Gross margin | 93.69% |
Operating margin | -141.35% |
Pretax margin | -71.38% |
Net margin | -73.20% |
Effective tax rate | -2.79% |
ROA | -10.50% |
ROE | -14.58% |
D/E | 0.30x |
Interest coverage ratio | -5.56x |
XNCR valuation
P/E | – |
P/S | 6.67x |
P/B | 1.33x |
P/CF | -6.27x |
P/FCF | -6.06x |
P/OCF | -6.27x |
PEG | -0.27x |
EV multiple | -14.91x |
About
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma.
Similar securities
Based on sector and market capitalization
